Q3/2024 9/30/2024 EPS -8.810 ZacksConsensus -6.250 ActVsEst (2.560) - Miss
Traws Pharma, Inc. (TRAW)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswire
- Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza TreatmentPR Newswire
- Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir MarboxilGlobeNewswire
- Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro InhibitorGlobeNewswire
TRAW
Earnings
- 5/15/24 - In-Line
TRAW
Sec Filings
- 11/15/24 - Form S-8
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- TRAW's page on the SEC website